CYP17 gene promoter allelic variant is not associated with prostate cancer

CMUR > College of Medicine > School of Medicine > Journal articles > Item 310903500/3680

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/3680

Title:	CYP17 gene promoter allelic variant is not associated with prostate cancer
Authors:	林正介(Cheng-Chieh Lin);吳錫金(Wu,Hsi-Chin);陳汶吉(Chen Wen-Chi);陳慧毅(Huey-Yi Chen);蔡輔仁(Fuu-Jen Tsai)
Contributors:	醫學院醫學系學士班家庭醫學科;中國附醫社區醫學部家庭醫學科
Keywords:	CYP17 gene;Prostate cancer;Cytochrome p450c17α enzyme;Single nucleotide polymorphisms (SNPs)
Date:	2003-07
Issue Date:	2009-08-20 18:49:15 (UTC+8)
Abstract:	Prostate cancer is the most common urological malignancy in Taiwan. The formation of prostate cancer has been reported to be associated with androgen. Two key steps in the sex steroid synthesis are mediated by the enzyme cytochrome P450c17α which is encoded in the CYP17 gene. Our aim was to investigate whether a polymorphism of CYP17 gene could be used as a genetic marker for associating prostate cancer. In this study, we compared the frequency of the C/T polymorphism of CYP17 gene 5′-UTR promoter region between 93 patients with prostate cancer and 121 healthy male volunteers (age, >60 years). The result revealed no significant association between the CYP17 genotype and prostate cancer (P = .781). Therefore, CYP17 C/T polymorphism is not a valid genetic marker for prostate cancer. Although a possible interaction between CYP17 gene C/T polymorphism and SP-1 transcription factor has been reported in the literature, we did not find any evidence for this the difference among clinical staging, pathological grading, or responsiveness to hormonal therapy in prostate cancer.
Relation:	UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 21(4):262~265
Appears in Collections:	[School of Medicine] Journal articles

Files in This Item:

File	Size	Format
	58Kb	Unknown	469	View/Open

Loading...